While endogenous FGF-21 appears to be ineffective at higher circulating FGF-21 levels, high pharmacological doses of FGF-21 analogues, agonistic antibodies or proteins targeting KLB could exert its effects and contribute to body weight reduction, glucose tolerance and lower circulating lipid levels [27,34,35]. This evidence concerns the gene FGF21 and glucose measurement.